Cytek Accounts Payable from 2010 to 2026

CTKB Stock  USD 4.43  0.09  2.07%   
Cytek Biosciences' Accounts Payable is increasing over the years with slightly volatile fluctuation. Accounts Payable is expected to dwindle to about 4 M. Accounts Payable is the amount Cytek Biosciences owes to suppliers or vendors for products or services received but not yet paid for. It represents Cytek Biosciences' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2020-12-31
Previous Quarter
6.9 M
Current Value
7.6 M
Quarterly Volatility
1.5 M
 
Covid
 
Interest Hikes
Check Cytek Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytek Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 386.4 K, Net Interest Income of 12.5 M or Interest Income of 12.5 M, as well as many indicators such as Price To Sales Ratio of 4.62, Dividend Yield of 0.0 or PTB Ratio of 2.02. Cytek financial statements analysis is a perfect complement when working with Cytek Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Cytek Stock
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.
Analyzing Cytek Biosciences's Accounts Payable over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Accounts Payable has evolved provides context for assessing Cytek Biosciences's current valuation and future prospects.

Latest Cytek Biosciences' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Cytek Biosciences over the last few years. An accounting item on the balance sheet that represents Cytek Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Cytek Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Cytek Biosciences' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytek Biosciences' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Cytek Accounts Payable Regression Statistics

Arithmetic Mean3,123,419
Geometric Mean2,937,513
Coefficient Of Variation40.78
Mean Deviation961,699
Median2,342,000
Standard Deviation1,273,786
Sample Variance1.6T
Range4M
R-Value0.75
Mean Square Error764.7B
R-Squared0.56
Significance0.0006
Slope188,452
Total Sum of Squares26T

Cytek Accounts Payable History

2026M
20256.4 M
20245.5 M
2023M
20224.8 M
2021M
20202.9 M

About Cytek Biosciences Financial Statements

Cytek Biosciences stakeholders use historical fundamental indicators, such as Cytek Biosciences' Accounts Payable, to determine how well the company is positioned to perform in the future. Although Cytek Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cytek Biosciences' assets and liabilities are reflected in the revenues and expenses on Cytek Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cytek Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable6.4 MM

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cytek Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytek Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytek Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytek Biosciences Stock:
Check out the analysis of Cytek Biosciences Correlation against competitors.
For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. Projected growth potential of Cytek fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytek Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
0.735
Earnings Share
(0.11)
Revenue Per Share
1.538
Quarterly Revenue Growth
0.015
Return On Assets
(0.04)
Investors evaluate Cytek Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytek Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Cytek Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytek Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytek Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytek Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.